Clinical Trial Update: Tarceva Italian Lung Optimization tRial [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial of Tarceva (erlotinib) for non-small cell lung cancer conducted in Italy is listed with an unknown status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Tarceva (erlotinib)

Snippet

Sponsor: Fatebenefratelli and Ophthalmic Hospital | Conditions: Non Small Cell Lung Cancer (NSCLC) | Phase 3 | Status: UNKNOWN